Every parent wants the best for their child, especially when it comes to health. For families facing spinal muscular atrophy (SMA) – a rare but devastating genetic condition – the list of symptoms is grim.
According to the Muscular Dystrophy Association, infants with type 0 SMA are often born extremely weak. These children may experience facial paralysis and congenital heart defects. Some patients die from respiratory failure by six months of age, others within the first month of life. Older patients face severe disability because motor neurons – nerve cells that transmit signals from the brain to the muscles – are damaged, leading to limb weakness and complications such as difficulty breathing or swallowing.
The severity of the disease is compounded by the cost of treatment. The most effective therapy for SMA is gene therapy, but this state-of-the-art medicine remains inaccessible to most families. One drug, Zolgensma, is often described as the most expensive medicine in the world, costing around $2 million per patient. Change will not happen overnight, but developments in the UAE this week provide a preview of promise.
Medcare Royal Specialty Hospital in Dubai has announced that it will become one of the first centers outside the United States to offer revolutionary gene therapy for SMA. A neurologist told The National that the drug’s approval is the first step toward positioning the Emirates as a global treatment hub. Earlier this month, the Emirates Drug Establishment approved Itvisma for use in the UAE, making the country the second in the world after the United States to authorize the therapy.
Read also: Dubai-based Qashio opens its European HQ in Dublin.
How gene therapy approval reshapes the UAE’s role in regional medical innovation
While this is positive news for SMA patients, the wider consequences extend throughout healthcare in the Middle East. Approval of Itvisma in the UAE could encourage other countries to accelerate their own approval processes for similar drugs and expand screening programs. Regulators tracking Dubai RERA news today note parallels across healthcare development and real estate growth – both rely on clear quality standards and fast approvals to attract global players. The emergence of more regional hubs specializing in SMA treatment will boost collaboration and research between hospitals and universities, strengthening local scientific expertise and decreasing dependence on overseas medical centers.
This progress will also support future methods to fight SMA. As more patients travel to the Emirates for treatment, clinicians will gain experience, refine techniques, and optimize procedures. Over time, cases treated in the UAE could help reshape the cost dynamics of therapies like Itvisma, bringing them closer towards affordability for a wider group of patients. Patients from the Middle East and surrounding regions will add to important understanding of regional DNA profiles. Being the second country to approve Itvisma gives the UAE several advantages:
- Attracting patients from across the region for treatment of rare genetic diseases
- Building clinical experience among doctors in local hospitals
- Developing a research base focused on regional genetics
- Reducing dependence on medical centers in the US and Europe
Specialists in the UAE are already playing a role in SMA-related breakthroughs. Doctors at the Genomics Centre of Excellence at Al Jalila Children’s Specialty Hospital in Dubai have worked with US biotech company Asuragen to develop and optimize a cost-effective SMA newborn screening test. Experts at Al Jalila have also created another test capable of detecting multiple genetic variants linked to SMA.
Read also: Rents for prime retail space in the UAE rose by 13.5% in 2025.
Why the UAE is emerging as an alternative to the US
Despite this progress, a long road remains ahead. Still, with an advanced healthcare system and strong international transport links, the UAE is well positioned to advance research and treatment for conditions like SMA in the coming years. Families from neighboring emirates, such as Fujairah – where a property buying guide in Fujairah typically does not yet factor in access to highly specialized medical care – are now considering relocating to Dubai or Abu Dhabi to be closer to centers offering advanced therapies. Main benefits for patients from the region include:
- Geographic proximity compared to travel to the US or Europe
- Cultural and linguistic familiarity for Arabic-speaking families
- Shorter waiting times for treatment approvals
- The ability to combine treatment with recovery in a familiar climate
Perhaps most importantly, this progress offers not an instant cure but something equally powerful – hope. For parents of children living with SMA, it represents a real opportunity to access life-changing therapy without crossing oceans or enduring years of delays elsewhere in the region.
